Inventurus Knowledge Solutions Limited has announced strong financial results for Q3FY26, demonstrating significant growth across key performance metrics with substantial EBITDA improvements and strategic business expansion. The technology-enabled healthcare solutions provider reported robust quarterly performance ended December 31, 2025.

Financial Performance Overview

The company delivered impressive consolidated results for Q3FY26, with substantial improvements across revenue, profitability, and operational efficiency metrics compared to the previous year.

Strategic Business Expansion

IKS Health continues to expand its reach through strategic partnerships that enhance financial performance and improve clinical efficiency for healthcare providers. Key business highlights include new partnerships with StrideCare, a Texas-based multi-specialty physician group, and expanded collaboration with VitalMD Group Holding encompassing ambient solutions from the Scribble Suite. The company also strengthened its partnership with a top 5 health system to include additional regions and states within RCM and Value-Based Care services.

Nine-Month Performance

For the nine months ended December 31, 2025, the consolidated performance showed consistent growth momentum across all major financial parameters.

Regulatory Filing and Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has filed its investor presentation on Q3FY26 financial results with BSE Limited and National Stock Exchange of India Limited. The presentation is also available on the company's website at ikshealth.com/investor-relations. Company Secretary and Compliance Officer Sameer Chavan signed the regulatory filing dated February 4, 2026.

Leadership Commentary and Market Position

Sachin K. Gupta, Founder & Global CEO, highlighted that the strong Q3 performance validates their Care Enablement Platform as a critical solution for the US healthcare market facing cost, quality, and access pressures. The company continues advancing AI capabilities, specifically moving Patient Engagement suite toward multi-agent orchestration for cognitive reasoning and independent action. Group CFO Nithya Balasubramanian emphasized that margin expansion results from successful operating leverage, technology deployment, and focused cost management.

Recognition and Awards

The company received significant industry recognition, winning a 2026 Best in KLAS Award for Virtual Scribing Services for the second consecutive year. Additionally, CEO Sachin K. Gupta won the ET Edge Impactful CEO Award in the Large Enterprise category, demonstrating the company's leadership position in healthcare technology solutions.

Inventurus knowledge solutions Limited has granted 122,000 employee stock options to eligible employees under its Employee Stock Option Plan 2022 (IKS ESOP Plan) on January 30, 2026. The grant was approved by the Nomination and Remuneration Committee of the Board of Directors in accordance with SEBI regulations.

ESOP Grant Details

The company has disclosed the grant under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The options were granted in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Pricing and Market Alignment

The exercise price of Rs. 1,537.10 per option has been set at not less than the market price, based on the closing price on January 29, 2026, on the National Stock Exchange of India Limited. The NSE was selected as the reference exchange due to having the highest trading volume, representing the trading day immediately preceding the date of the Nomination and Remuneration Committee's approval.

Key Terms and Conditions

Each option is convertible into one fully paid-up equity share of the company. The IKS ESOP Plan is administered through a Trust structure, ensuring proper governance and compliance. The stock options granted can be exercised anytime during the entire period of continuous active employment from the date of vesting of the respective options.

Plan Features

• Options administered through Trust structure
• Each option converts to one equity share of Re. 1 face value
• Exercise permitted during continuous employment period
• Provisions for corporate actions and adjustments
• No lock-in period for allotted equity shares

Regulatory Compliance

The ESOP scheme operates in full compliance with SEBI (SBBEB) Regulations, 2021. The plan includes comprehensive provisions for handling stock options in various scenarios including death, permanent incapacity, resignation, termination, and retirement of employees. Additionally, the scheme provides for appropriate adjustments in case of corporate actions such as rights issues, bonus issues, stock splits, mergers, or other reorganizations.

The company has filed the necessary disclosures with both BSE Limited (Scrip Code: 544309) and National Stock Exchange of India Limited (Symbol: IKS) as required under the regulatory framework. The equity shares that will be allotted upon exercise of these stock options will not be subject to any lock-in restrictions, providing flexibility to employees upon vesting and exercise.